3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma
19
Lymphoma, Large B-Cell, Diffuse
17
Hodgkin Disease
8
Lymphoma, Non-Hodgkin
7
Lymphoma, Follicular
5
Leukemia
5
Hemangioma
5
Lymphoma, Large-Cell, Anaplastic
4
Prostatic Neoplasms
3
Neoplasms
3
Lymphoma, B-Cell
3
Immunoblastic Lymphadenopathy
3
Neurotoxicity Syndromes
2
Neoplasm, Residual
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Esophageal Stenosis
2
Enteropathy-Associated T-Cell Lymphoma
2
Vomiting
1
Thymoma
1
Recurrence
1
Pulmonary Disease, Chronic Obstructive
1
Polycystic Ovary Syndrome
1
Philadelphia Chromosome
1
Neoplasm Metastasis
1
Neoadjuvant Therapy
1
Nausea
1
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
Prednisolone
×
Clear all
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled